FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1930452111> ?p ?o ?g. }

• W1930452111 endingPage "595" @default.
• W1930452111 startingPage "587" @default.
• W1930452111 abstract "PURPOSE This phase I/II study was designed to explore the feasibility, toxicity, and potential efficacy of administering high-dose continuous intravenous mercaptopurine (6MP) followed by intermediate-dose continuous intravenous cytarabine (Ara-C) to children with relapsed or unresponsive acute leukemia. PATIENTS AND METHODS Twenty-three children with relapsed or unresponsive acute leukemia (13 myeloid, 10 lymphoid) were entered onto the study. After initial hydration and alkalinization, 1,000 or 1,250 mg/m2 of 6MP was administered by continuous intravenous infusion over 24 hours. Following another period of hydration, 500 mg/m2 of Ara-C was administered by continuous intravenous infusion daily for 4 days. In 17 children, plasma concentrations of 6MP were measured at hours 4, 24, and 27 of the 6MP infusions. Plasma concentrations of Ara-C were measured at hours 8, 24, 48, 72, and 96 of the Ara-C infusions. Intracellular Ara-C triphosphate (Ara-CTP) concentrations were measured in peripheral-blood leukemia cells of the five patients with sufficient cells for measurement. Children who developed remission received repeated courses of this regimen every 3 to 4 weeks until relapse or completion of 12 courses. RESULTS Of 13 children with acute myeloid leukemia (AML), six developed complete remissions (CRs) lasting 7 months to nearly 4 years. Two children remain in CR with normal growth, development, and health 3 years after cessation of treatment. Of 10 children with acute lymphoid leukemia (ALL), one had a CR of 2 months' duration. Dose-limiting toxicity consisted of severe hematosuppression with fever, neutropenia, and serious infection. There were two toxic deaths. The mean steady-state plasma concentrations of 6MP were approximately 4 mumol/L and of Ara-C approximately 3 mumol/L. The median Ara-CTP concentration in peripheral-blood leukemia cells was 308 mumol/L at hour 8 of the Ara-C infusion. CONCLUSION High-dose continuous intravenous 6MP followed by intermediate-dose intravenous Ara-C produced CRs of longer than 6 months in approximately half of children with relapsed or unresponsive AML. Further study of this drug regimen is justified." @default.
• W1930452111 created "2016-06-24" @default.
• W1930452111 creator A5007711247 @default.
• W1930452111 creator A5020655018 @default.
• W1930452111 creator A5036290225 @default.
• W1930452111 creator A5044030725 @default.
• W1930452111 creator A5082329495 @default.
• W1930452111 creator A5089159215 @default.
• W1930452111 creator A5090441572 @default.
• W1930452111 date "1994-03-01" @default.
• W1930452111 modified "2023-10-18" @default.
• W1930452111 title "High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia." @default.
• W1930452111 cites W1507403192 @default.
• W1930452111 cites W1526531042 @default.
• W1930452111 cites W1532372829 @default.
• W1930452111 cites W1606856073 @default.
• W1930452111 cites W1828655749 @default.
• W1930452111 cites W1907898477 @default.
• W1930452111 cites W1937894144 @default.
• W1930452111 cites W1992814856 @default.
• W1930452111 cites W2012891007 @default.
• W1930452111 cites W2025935171 @default.
• W1930452111 cites W2047605301 @default.
• W1930452111 cites W2063305040 @default.
• W1930452111 cites W2072032394 @default.
• W1930452111 cites W2090134648 @default.
• W1930452111 cites W2096748176 @default.
• W1930452111 cites W2118234018 @default.
• W1930452111 cites W2128036895 @default.
• W1930452111 cites W2146197778 @default.
• W1930452111 cites W2396436656 @default.
• W1930452111 cites W2409394724 @default.
• W1930452111 cites W2412338107 @default.
• W1930452111 cites W2415766665 @default.
• W1930452111 cites W2461862515 @default.
• W1930452111 cites W69394743 @default.
• W1930452111 cites W1837285654 @default.
• W1930452111 doi "https://doi.org/10.1200/jco.1994.12.3.587" @default.
• W1930452111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8120558" @default.
• W1930452111 hasPublicationYear "1994" @default.
• W1930452111 type Work @default.
• W1930452111 sameAs 1930452111 @default.
• W1930452111 citedByCount "16" @default.
• W1930452111 countsByYear W19304521112013 @default.
• W1930452111 countsByYear W19304521112014 @default.
• W1930452111 crossrefType "journal-article" @default.
• W1930452111 hasAuthorship W1930452111A5007711247 @default.
• W1930452111 hasAuthorship W1930452111A5020655018 @default.
• W1930452111 hasAuthorship W1930452111A5036290225 @default.
• W1930452111 hasAuthorship W1930452111A5044030725 @default.
• W1930452111 hasAuthorship W1930452111A5082329495 @default.
• W1930452111 hasAuthorship W1930452111A5089159215 @default.
• W1930452111 hasAuthorship W1930452111A5090441572 @default.
• W1930452111 hasConcept C126322002 @default.
• W1930452111 hasConcept C2776694085 @default.
• W1930452111 hasConcept C2777063308 @default.
• W1930452111 hasConcept C2777173762 @default.
• W1930452111 hasConcept C2778041864 @default.
• W1930452111 hasConcept C2778461978 @default.
• W1930452111 hasConcept C2778729363 @default.
• W1930452111 hasConcept C2778850193 @default.
• W1930452111 hasConcept C2779282312 @default.
• W1930452111 hasConcept C2781107101 @default.
• W1930452111 hasConcept C2781413609 @default.
• W1930452111 hasConcept C2909962599 @default.
• W1930452111 hasConcept C29730261 @default.
• W1930452111 hasConcept C71924100 @default.
• W1930452111 hasConcept C90924648 @default.
• W1930452111 hasConceptScore W1930452111C126322002 @default.
• W1930452111 hasConceptScore W1930452111C2776694085 @default.
• W1930452111 hasConceptScore W1930452111C2777063308 @default.
• W1930452111 hasConceptScore W1930452111C2777173762 @default.
• W1930452111 hasConceptScore W1930452111C2778041864 @default.
• W1930452111 hasConceptScore W1930452111C2778461978 @default.
• W1930452111 hasConceptScore W1930452111C2778729363 @default.
• W1930452111 hasConceptScore W1930452111C2778850193 @default.
• W1930452111 hasConceptScore W1930452111C2779282312 @default.
• W1930452111 hasConceptScore W1930452111C2781107101 @default.
• W1930452111 hasConceptScore W1930452111C2781413609 @default.
• W1930452111 hasConceptScore W1930452111C2909962599 @default.
• W1930452111 hasConceptScore W1930452111C29730261 @default.
• W1930452111 hasConceptScore W1930452111C71924100 @default.
• W1930452111 hasConceptScore W1930452111C90924648 @default.
• W1930452111 hasIssue "3" @default.
• W1930452111 hasLocation W19304521111 @default.
• W1930452111 hasLocation W19304521112 @default.
• W1930452111 hasOpenAccess W1930452111 @default.
• W1930452111 hasPrimaryLocation W19304521111 @default.
• W1930452111 hasRelatedWork W130051642 @default.
• W1930452111 hasRelatedWork W189281016 @default.
• W1930452111 hasRelatedWork W1945820803 @default.
• W1930452111 hasRelatedWork W2000475715 @default.
• W1930452111 hasRelatedWork W2336649003 @default.
• W1930452111 hasRelatedWork W2560259057 @default.
• W1930452111 hasRelatedWork W2589373649 @default.
• W1930452111 hasRelatedWork W4229655155 @default.
• W1930452111 hasRelatedWork W4312909839 @default.
• W1930452111 hasRelatedWork W4381480068 @default.

• next